GlassScriptPhysician profile
Gary J Guzzardo
NPI 1669552717
$1,324.31
in general payments reported to CMS, 2019-2025
14 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $107 · 2021: $341 · 2022: $219 · 2023: $196 · 2024: $101 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246 · Gift: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.72 |
| Gift | $161.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $615.66 | 2019-2025 | Suflave, Sutab |
| Takeda Pharmaceuticals U.S.A., INC. | $149.61 | 2019-2025 | Entyvio |
| Janssen Scientific Affairs, LLC | $102.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $99.59 | 2021 | |
| Ironwood Pharmaceuticals, INC | $73.28 | 2020-2022 | |
| Celgene Corporation | $45.97 | 2021-2022 | |
| Abbvie INC. | $45.43 | 2022-2025 | |
| Redhill Biopharma INC. | $45.20 | 2020-2021 | |
| Pacira Pharmaceuticals Incorporated | $32.10 | 2019-2024 | Exparel |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.55 | 2019-2021 | |
| Novo Nordisk INC | $28.45 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $21.47 | 2024 | Voquezna |
| Janssen Biotech, INC. | $20.56 | 2019 | |
| Allergan, INC. | $14.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Guzzardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.